SEC Form 4 · accession 0001179110-16-024906
DAVITA INC. · DVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Javier Rodriguez
Officer — CEO-Kidney Care
Period of report
May 13, 2016
Accepted (ET)
May 17, 2016 · 6:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000927066
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | May 16, 2016 | S | 36,466 | $75.4427 | D | 64,264 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation RightsF3 | $75.42 | May 13, 2016 | A | 124,091 | A | May 13, 2019 | May 13, 2021 | Common Stock | 124,091 | 124,091 | D |
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2015.
- F2Represents the weighted average sale price of $75.4427. The range of prices for the sale of these shares was $75.20 - $75.96, rounded to the nearest hundredth. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F3The Stock Appreciation Rights were granted on 5/13/2016. 50% will vest on 5/13/2019 and the remaining 50% will vest on 5/13/2020.